uniQure Researchers Swap Out Lead Drug for a Better Prospect Post author:Sam Post published:October 18, 2017 Post category:BioPharma The company plans to expeditiously advance AMT-061 instead of AMT-060. Source: BioSpace You Might Also Like Argenx Announces Full Exercise Of Underwriters' Option To Purchase Additional ADSs May 18, 2017 Attention Bay Area: BIOHUB is Hiring Lots of Scientists February 1, 2017 FDA Hails Novartis' Kisqali a Breakthrough January 2, 2018
